CD66e (CEA) Monoclonal Antibody (CB30), eBioscience™, Invitrogen™

Description

• Description: The monoclonal antibody CB30 recognizes human CD66e, also known as CEA (carcinoembryonic antigen) and CEACAM5
• As a member of the immunoglobulin superfamily, it is large GPI-linked glycosylated protein with a molecular weight about 200 kDa
• It is expressed mainly on epithelial cells and on a variety of tumors of the gastrointestinal, respiratory and genitourinary tracts
• CD66e has been shown to function in cell adhesion and migration via homophilic and heterophilic interactions with NCA (non-specific cross-reacting antigen also known as CEACAM6 and CD66c)
• Overexpression is correlated with tumor invasiveness and is therefore used as a clinical marker
• Applications Reported: This CB30 antibody has been reported for use in flow cytometric analysis, immunoblotting (WB), and immunohistochemical staining
• Applications Tested: This CB30 antibody has been tested by immunohistochemistry and by western blot on cell lysates prepared from MCF7 cells
• This antibody can be used at less than or equal to 1 μg/mL for immunoblotting and less than 10 μg/mL for IHC
• It is recommended that this antibody be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• CEA (Carcino Embryonic Antigen, CD66e) is synthesized during development in the fetal gut, and re-expressed in increased amounts in intestinal carcinomas and several other tumors
• CEA is a member of carcinoembryonic antigens, immunoglobulin supergene family and consists of a single N domain (structural homology to the immunoglobulin variable) and six immunoglobulin constant-like A (A1, A2, A3) and B domains (B1, B2, B3)
• Antibodies to CEA are useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60 to 70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+)
• CEA is a member of a large family of glycoproteins, a useful tumor marker for adenocarcinoma, and found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon
• Two subgroups of the CEA family, the CEA cell adhesion molecules and the pregnancy-specific glycoproteins, are located within a 1.2 Mb cluster on the long arm of chromosome 19
• Eleven pseudogenes of the CEA cell adhesion molecule subgroup are also found in the cluster
• CEA was originally described in bile ducts of liver as biliary glycoprotein
• Subsequently, CEA was found to be a cell-cell adhesion molecule detected on leukocytes, epithelia, and endothelia
• The encoded protein mediates cell adhesion via homophilic as well as heterophilic binding to other proteins of the subgroup
• Multiple cellular activities have been attributed to the encoded protein, including roles in the differentiation and arrangement of tissue three-dimensional structure, angiogenesis, apoptosis, tumor suppression, metastasis, and the modulation of innate and adaptive immune responses
• Multiple transcript variants encoding different isoforms have been reported, but the full-length nature of all variants has not been defined.